This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

PharmAthene Progresses Second Generation RPA Anthrax Vaccine

ANNAPOLIS, Md., Oct. 31, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today further development progress of its second generation rPA anthrax vaccine, SparVax™.  The new vaccine is being developed to provide rapid manufacturing scale-up to respond to a national security emergency.  The Company completed its first cGMP manufacturing run at 1,500 liter commercial scale.  Final analytical testing is ongoing and expected to be completed in December.

"There is widespread acknowledgement of the need for a modern, next-generation anthrax vaccine that can meet the government's needs in the event of an emergency.  A recombinant anthrax vaccine offers the potential for an improved vaccine that is safe, convenient, cost-effective and provides for a significant increase in production yields," remarked Eric I. Richman, President and Chief Executive Officer. "SparVax™ is the first medical countermeasure to successfully transition from early research funded by the National Institutes of Health (NIH) to advanced development in partnership with the Biomedical Advanced Research and Development Authority (BARDA).  SparVax™ represents how our medical countermeasure development program can create products with desired characteristics to meet the needs of our country.  We look forward to continuing a very productive collaboration with our partners in government to address this need and advance this important product."

"This achievement marks the latest in a series of accomplishments for our rPA anthrax vaccine program in 2011," commented Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer. "Earlier this year, we successfully completed the technology transfer of our manufacturing process from the United Kingdom to a United States-based contract manufacturing organization.  Most importantly, PharmAthene has data supporting 36 months of stability for SparVax™ – an important accomplishment given the historical issues associated with rPA anthrax vaccine stability.  The use of recombinant vaccine technology employing modern, industrial biotechnology manufacturing processes provides the flexibility to produce a well-characterized product that can be rapidly scaled-up for production in the event of a national emergency.  

A key differentiator for PharmAthene's rPA technology platform is the utilization of E. coli.  This technology enables a more robust manufacturing process and the capability of annually producing more than 150 million rPA vaccine equivalent doses of bulk drug substance (at a 50 mcg dose) – a substantial improvement in  rPA production yield without the production of destructive proteases. In addition, PharmAthene's manufacturing platform has the ability to produce stable production intermediates in the event surge capacity is required.  All these factors contribute to key advantages of SparVax™ over other rPA-based anthrax vaccine programs."

PharmAthene's rPA anthrax vaccine program has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health and the Biomedical Advanced Research and Development Authority.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,979.13 +59.54 0.35%
S&P 500 1,986.51 +4.91 0.25%
NASDAQ 4,526.4820 -1.0320 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs